{
  "id": "e3ac758e-7826-45ff-9fb0-18f3012ee834",
  "title": "Bionano Genomics outlines 2025 revenue guidance of $29M-$32M with strategic focus on utilization",
  "link": "https://seekingalpha.com/news/4427213-bionano-genomics-outlines-2025-revenue-guidance-of-29m-32m-with-strategic-focus-on?utm_source=feed_news_all\u0026utm_medium=referral\u0026feed_item_type=news",
  "description": "",
  "author": "",
  "published": "Mon, 31 Mar 2025 20:12:22 -0400",
  "source": "https://seekingalpha.com/market_currents.xml",
  "categories": [
    "bngo"
  ],
  "byline": "SA Transcript Insights Editor",
  "length": 1042,
  "excerpt": "Discover Bionano Genomics' Q4 2024 earnings insights, focusing on operational efficiency, core customer utilization, and 2025 growth strategies with new CPT...",
  "siteName": "Seeking Alpha",
  "favicon": "https://seekingalpha.com/samw/static/images/favicon-192x192.png",
  "text": "Earnings Call Insights: Bionano Genomics (BNGO) Q4 2024 Management View CEO Erik Holmlin highlighted a strategic shift toward optimizing the utilization of existing optical genome mapping (OGM) systems among core customers. The company aims to focus its efforts on its 118 routine useSeeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts here. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.",
  "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
  "html": "\u003cdiv id=\"readability-page-1\" class=\"page\"\u003e\u003cdiv data-test-id=\"card-container\"\u003e\u003cheader\u003e\u003c/header\u003e\u003cdiv data-test-id=\"content-container\"\u003e\u003cp\u003eEarnings Call Insights: Bionano Genomics (BNGO) Q4 2024\u003c/p\u003e \u003ch3\u003eManagement View\u003c/h3\u003e \u003cul\u003e\u003cli\u003eCEO Erik Holmlin highlighted a strategic shift toward optimizing the utilization of existing optical genome mapping (OGM) systems among core customers. The company aims to focus its efforts on its 118 routine use\u003c/li\u003e\u003c/ul\u003e\u003c/div\u003e\u003cp\u003e\u003cstrong\u003eSeeking Alpha\u0026#39;s Disclaimer: \u003c/strong\u003eThe earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed. Please see full earnings call transcripts \u003ca href=\"https://seekingalpha.com/symbol/BNGO/earnings/transcripts\"\u003ehere\u003c/a\u003e. The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.\u003c/p\u003e\u003c/div\u003e\u003c/div\u003e",
  "readingTime": "2 min read",
  "publishedTime": "2025-04-01T00:12:22Z",
  "modifiedTime": null
}
